PLIVA Completes Divestment of Research Institute
PLIVA d.d. announced that it has completed the divestment of PLIVA - Istrazivaki Institut d.o.o. (PLIVA - Research Institute Ltd.), PLIVA's proprietary R&D arm to GlaxoSmithKline (GSK).
PLIVA received a payment of USD 35m upon closing of the transaction and is entitled to contingent payments totaling up to USD 15m conditional on the entry of certain early stage projects into clinical development. In addition, PLIVA will receive contingent royalty-based consideration pending commercialisation of certain assets.
The closing of the transaction will positively impact PLIVA Group results by an exceptional gain on sale of the discontinued business of about USD 20m in the second quarter 2006. Ongoing financing of the discontinued proprietary R&D operations through to closing will also impact PLIVA Group results by about USD 6m. Both items will be recorded below the operating line (EBIT).
Most read news
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.